{"nctId":"NCT02933866","briefTitle":"Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis","startDateStruct":{"date":"2016-03-11","type":"ACTUAL"},"conditions":["Scalp Psoriasis"],"count":371,"armGroups":[{"label":"DSXS topical","type":"EXPERIMENTAL","interventionNames":["Drug: DSXS topical"]},{"label":"Vehicle topical","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle topical"]}],"interventions":[{"name":"DSXS topical","otherNames":["Active"]},{"name":"Vehicle topical","otherNames":["placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or non-pregnant, non-lactating females 18 years of age and older.\n\nExclusion Criteria:\n\n* Females who are pregnant, lactating or likely to become pregnant during the study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Patients in Each Treatment Group Who Are Considered a Clinical Success","description":"Clinical Success is defined by an IGA score of 0 (clear) or I (almost clear) with at least a 2 grades reduction from baseline at Day 29 Â± 2","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":183},"commonTop":["Headache","Eye irritation","Application site pain","Application site pruritus","Nasopharyngitis"]}}}